The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease
Abstract
RATIONALE: Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-related, inflammatory lung disease in which tumor necrosis factor-alpha is overexpressed and has been suggested to play a pathogenic role. OBJECTIVES: To determine if infliximab, an anti-TNF-alpha antibody, results in clinical benefit and has an acceptable safety profile in patients with moderate to severe COPD. METHODS: In a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study, subjects with moderate to severe COPD received infliximab (3 mg/kg [n = 78] or 5 mg/kg [n = 79]) or placebo (n = 77) at Weeks 0, 2, 6, 12, 18, and 24. Efficacy, health status, and safety were assessed through Week 44. MEASUREMENTS AND MAIN RESULTS: Infliximab was generally well tolerated, but showed no treatment benefit as measured by the primary endpoint, Chronic Respiratory Questionnaire total score. Similarly, there was no change in secondary measures, including prebronchodilator FEV(1), 6-min walk distance, SF-36 physical score, transition dyspnea index, or moderate-to-severe COPD exacerbations. Post hoc analysis revealed that subjects who were younger or cachectic showed improvement in the 6-min walk distance. Malignancies were diagnosed during the study in 9 of 157 infliximab-treated subjects versus 1 of 77 placebo-treated subjects. No opportunistic infections were observed, and there were no differences in the occurrence of antibiotic-requiring infections, although the incidence of pneumonia was higher in infliximab-treated subjects. No infection-related mortality was observed. Higher proportions of infliximab-treated subjects discontinued the study agent due to adverse events (20-27%) than did placebo-treated subjects (9%). CONCLUSIONS: Subjects with moderate to severe COPD did not benefit from treatment with infliximab. Although not statistically significant, more cases of cancer and pneumonia were observed in the infliximab-treated subjects. The impact of infliximab on malignancy risk in patients with COPD needs to be further elucidated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. (1985) · Europe PMC (PubMed Central) · Cited by 2,401
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Wilson, A. G., Symons, J. A., McDowell, T. L., McDevitt, H. O., & Duff, G. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3195 · Cited by 2,218
A measure of quality of life for clinical trials in chronic lung disease
Guyatt, G. H., Berman, L. B., Townsend, M., Pugsley, S. O., & Chambers, L. W. (1987) · Thorax · doi:10.1136/thx.42.10.773 · Cited by 1,721 · cited 1×
“Subjects were required to have less than a 20% increase in FEV1 after a fixed dose of bronchodilator (180 g inhaled albuterol), a history of at least 10 pack-years of smoking, have at least one episode of COPD-related symptoms (e.g., cough, sputum production, shortness of breath) within the 2 months before screening,…”
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Self-citationMahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Self-citationWeight Loss Is a Reversible Factor in the Prognosis of Chronic Obstructive Pulmonary Disease
SCHOLS, A. M. W. J., SLANGEN, J., VOLOVICS, L., & WOUTERS, E. F. M. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9705017 · Cited by 1,085
Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease
Troosters, T., Casaburi, R., Gosselink, R., & Decramer, M. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1109so · Cited by 649
Cellular and Structural Bases of Chronic Obstructive Pulmonary Disease
SAETTA, M., TURATO, G., MAESTRELLI, P., MAPP, C. E., & FABBRI, L. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.6.2009116 · Cited by 552
Tumor necrosis factor or tumor promoting factor?
Balkwill, F. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00020-x · Cited by 520
Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease.
Di Francia, M., Barbier, D., Mege, J. L., & Orehek, J. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.5.7952575 · Cited by 485
Kotler, D., Burastero, S., Wang, J., & Pierson, R. (1996) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/64.3.489s · Cited by 472
AARON, S. D., ANGEL, J. B., LUNAU, M., WRIGHT, K., FEX, C., LE SAUX, N., & DALES, R. E. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.2.2003122 · Cited by 466
Tumor Necrosis Factor-α Drives 70% of Cigarette Smoke–induced Emphysema in the Mouse
Churg, A., Wang, R. D., Tai, H., Wang, X., Xie, C., & Wright, J. L. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-511oc · Cited by 348
Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients.
de Godoy, I., Donahoe, M., Calhoun, W. J., Mancino, J., & Rogers, R. M. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.2.8564110 · Cited by 334
COPD: current therapeutic interventions and future approaches
Barnes, P. J., & Stockley, R. A. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00139104 · Cited by 259
Cytokines, apoptosis and cachexia: the potential for TNF antagonism
Sharma, R., & Anker, S. D. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00244-9 · Cited by 179
SAKAO, S., TATSUMI, K., IGARI, H., SHINO, Y., SHIRASAWA, H., KURIYAMA, T., & Association of Non-University-Affiliated Pulmonary Specialist Physicians of Chiba University School of Medicine (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.2.2006031 · Cited by 170
Limb Muscle Dysfunction in COPD: Effects of Muscle Wasting and Exercise Training
Franssen, F. M. E., Broekhuizen, R., Janssen, P. P., Wouters, E. F. �., & Schols, A. M. W. J. (2005) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000150082.59155.4f · Cited by 162
Tumor necrosis factor-? in the pathogenesis and treatment of cancer
ANDERSON, G., Nakada, M. T., & deWitte, M. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.04.004 · Cited by 156
Zheng, T., Kang, M., Crothers, K. A., Zhu, Z., Liu, W. Q., Lee, C. G., Rabach, L. A., Chapman, H. A., Homer, R., Aldous, D., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.8106 · Cited by 151
First Study of Infliximab Treatment in Patients with Chronic Obstructive Pulmonary Disease
van der Vaart, H., Koëter, G. H., Postma, D. S., Kauffman, H. F., & ten Hacken, N. H. T. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200501-147oc · Cited by 140
Engele, M., Stöβel, E., Castiglione, K., Schwerdtner, N., Wagner, M., Bölcskei, P., Röllinghoff, M., & Stenger, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1328 · Cited by 130
Keatings, V. M., Cave, S., Henry, M. J., Morgan, K., O'CONNOR, C. M., FitzGerald, M. X., & Kalsheker, N. A. (2000) · CHEST Journal · doi:10.1378/chest.118.4.971 · Cited by 106
Schmidt-Ioanas, M., Pletz, M. W., Roux, A. D., & Lode, H. M. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.08.011 · Cited by 15
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
Inflammatory mechanisms in patients with chronic obstructive pulmonary disease
Barnes, P. J. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.011 · Cited by 1,683
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
COPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Metadata
- Authors
- Rennard, S. I., Fogarty, C., Kelsen, S., Long, W., Ramsdell, J., Allison, J., Mahler, D., Saadeh, C., Siler, T., Snell, P., Korenblat, P., Smith, W., Kaye, M., Mandel, M., Andrews, C., Prabhu, R., Donohue, J. F., Watt, R., Lo, K. H., Schlenker-Herceg, R., Barnathan, E. S., & Murray, J.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-01
- Volume
- 175
- Issue
- 9
- Pages
- 926-934
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W1996136023
- Cited by
- 439
- References
- 31
- FWCI
- 36.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.